Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002324 · ClinicalTrials.gov registry record · NA
Tailoring of Vaccine-Focused Messages: Disease Salience
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 1,320
- Enrollment target
NCT03002324: Completed NA study, sponsored by Emory University.
NCT03002324 is a NA study that has completed, run by Emory University. The registered enrollment target is 1,320 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03002324, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,320 participants
- Enrollment target
Study Summary
This study is the second phase of a trial examining decision making about vaccines. For this phase of this study, the researchers will conduct a 3-arm randomized trial to compare the current Centers for Disease Control and Prevention (CDC) human papillomavirus (HPV) message, a new cervical cancer focused message developed by the study team, and a non-vaccine related control passage among parents of adolescent females. The goal of the trial will be to determine if the new cervical cancer framed message has an increased impact on intent to have daughters receive the HPV vaccine over the trial period as compared to the current CDC message used in the field. Additionally, the researchers will examine the impact both the CDC message and the new message individually have on intent to vaccinate when compared to the non-vaccine related control message. The participant's vaccine beliefs and intent to vaccinate will be assessed through an online survey at baseline. Two weeks later, participants will be randomized to view one of the three messages: the current CDC message, the cervical cancer framed message, or a non-vaccine related control message. Immediately afterwards, vaccine beliefs and intent to vaccinate will be assessed to determine the impact of the message.
Primary Outcome
Number of caregivers experiencing a change in attitude towards the HPV vaccine
Interventions
- BEHAVIORAL Baseline Survey
- BEHAVIORAL Control Message
- BEHAVIORAL Current CDC Message
- BEHAVIORAL Cervical Cancer Message
- BEHAVIORAL Post-Intervention Survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,320 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-05-01 |
| Phase | NA |
What the finished NCT03002324 record still lists
NCT03002324 is an interventional study that assigns participants to a tested intervention. Its 1,320 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Baseline Survey is the first listed.
NCT03002324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03002324 about?
NCT03002324 is a clinical study titled "Tailoring of Vaccine-Focused Messages: Disease Salience". This study is the second phase of a trial examining decision making about vaccines. For this phase of this study, the researchers will conduct a 3-arm randomized trial to compare the current Centers for Disease Control and Prevention (CDC) human papillomavirus (HPV) message, a new cervical cancer fo...
What is the current status of trial NCT03002324?
This trial is currently completed. It is a NA study. The enrollment target is 1,320 participants. The study started on 2017-01. Estimated completion is 2017-05-01.
What interventions are being tested in trial NCT03002324?
The interventions under investigation include: Baseline Survey (BEHAVIORAL), Control Message (BEHAVIORAL), Current CDC Message (BEHAVIORAL), Cervical Cancer Message (BEHAVIORAL), Post-Intervention Survey (BEHAVIORAL).
Who is sponsoring clinical trial NCT03002324?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03002324's enrollment target sits among peer trials
1,320 75th of 2000 higher than 1,926 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06557005 · 1,320 participants · NA
Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions
- NCT07213908 · 1,320 participants · NA
Comparing Two School-Based Sleep Health Interventions To Promote Sleep Quality in Youth
- NCT07144800 · 1,319 participants · NA
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
- NCT05097287 · 1,324 participants · Phase 4
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia